Drug Database
Back to search

Poland· PL-100098326

Edronax

A reboxetine product containing reboxetinum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 8 of our 19 countries.

ATC N06AX18

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedEdronaxATCN06AX18REGISTER NO.PL-100098326PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about reboxetinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Reboxetine is registered in 8 of 19 countries.

Countries holding a registration under ATC N06AX18 (reboxetine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose
Search reboxetine products by name

Reboxetine · ATC N06AX18

8 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Germany
  • Ireland
  • Italyprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of reboxetine costs, country by country.

Normalised to the WHO defined daily dose (8 mg), the median price runs from $1.04 in Italy to $2.27 in Switzerland — a ×2.2 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Reboxetine · price per daily dose (8 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$2.27
  • IT Italy$1.04
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Reboxetinum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
N06AX18
ATC class
Reboxetine
Defined daily dose
8 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05909990841622
  • gtin
    05909990841615
  • gtin
    05415062129678
  • gtin
    05415062129685

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

19 interactions on record for reboxetine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check reboxetine against other medicinesHow interaction checks work

Reboxetine · interactions on record

19 records

19 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Reboxetine in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All reboxetine products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Edronax
  • Belgium · Edronax
  • Bulgaria · Едронакс
  • Germany · Edronax
  • Spain · Irenor, Norebox
  • United Kingdom (Northern Ireland) · Edronax
  • Croatia · Edronax
  • Ireland · Edronax
  • Italy · Edronax
  • Luxembourg · Edronax
  • Portugal · Edronax
  • Sweden · Edronax
  • Slovenia · Edronax

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/326d0a82-901f-4184-a352-5154adc81e45
GET /v1/drugs/326d0a82-901f-4184-a352-5154adc81e45?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "4 mg",
  "packaging": "05909990841622 ¦ Rp ¦ 16776\n60 tabl. w blistrze\n05909990841615 ¦ Rp ¦ 47871\n20 tabl. w blistrze\n05415062129678 ¦ Rp ¦ 162851\n20 tabl. w butelce\n05415062129685 ¦ Rp ¦ 162852\n60 tabl. w butelce",
  "substance": "Reboxetinum 4 mg",
  "common_name": "Reboxetinum",
  "pl_product_id": "100098326",
  "pozwolenie_nr": "08416",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about reboxetine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console